Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: How well does daratumumab and nivolumab, when given with a vaccine, control or stop these types of cancer? How well does participants bodies handle these study drugs? Does this combination of study drugs help participants live longer? Participants will receive daratumumab, nivolumab with KRAS vaccine and have regular tests and procedures to follow how the participants are doing on these study drugs.

Official Title
-----------------
A Phase 2 Study Evaluating the Efficacy of Anti-CD38 Antibody in Combination With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Conditions
-----------------
Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: Daratumumab
* Biological: KRAS vaccine
* Drug: Nivolumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Patients with advanced NSCLC, progressing on frontline anti-PD-1/PD-L1 containing therapy (patient with rapid tumor progression will be excluded) and PDAC patients who failed one prior treatment. Measurable disease as defined by irRECIST criteria (See Section 7) NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible. All patients with mutant KRAS status in either codon 12 (12A, C, D, R, S, V) or 13 (13D) will be included. The status of KRAS and LKB1 will be determined. For patients with KRAS G12C-mutated NSCLC, prior treatment with G12C-targeted therapy will be allowed; a wash-out period of 1 week from the last administration of targeted therapy would be allowed. Patients with known actionable driver alterations such as EGFR, ALK, ROS1, BRAF, NTRK1/2/3, METex14, RET, ERBB2 (HER2) and concurrent KRAS mutations will be reviewed on a case-by-case basis and patients must have experienced progression on appropriate first-line targeted therapy and anti-PD-1/PD-L1 as indicated. Prior treatment: For NSCLC: Anti-PD1/PD-L1 containing therapy; a wash-out period of 4 weeks from the last administration of therapy would be allowed. For PDAC: Patients who failed one prior treatment. Provide written informed consent. Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study). Ability to complete questionnaire(s) by themselves or with assistance. Willingness to provide mandatory blood specimens for correlative research. Willingness to provide mandatory tissue specimens for correlative research. ECOG Performance Status (PS) 0, 1 or 2. The following laboratory values obtained ≤14 days prior to registration: • Hemoglobin ≥9.0 g/dL Absolute neutrophil count (ANC) ≥1500/mm3 Platelet count ≥100,000/mm3 Total bilirubin ≤1.5 x ULN (upper limit of normal) ALT and AST ≤3 x ULN (≤5 x ULN for patients with liver involvement) PT (prothrombin time)/INR/aPTT (activated partial thromboplastin time) ≤1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy Calculated creatinine clearance (CrCl) ≥20 mL/min using the Cockcroft-Gault formula Negative pregnancy test done ≤7 days prior to registration, for persons of childbearing potential only. Exclusion Criteria: Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: • Pregnant persons Nursing persons Persons of childbearing potential who are unwilling to employ adequate contraception Any of the following prior therapies: • Daratumumab or other anti-CD38 therapies Surgery ≤3 weeks prior to registration Chemotherapy ≤4 weeks prior to registration For NSCLC: anti-PD-1/PD-L1 therapy ≤4 weeks prior to registration; for PDAC: Prior treatment with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways. Focal radiation therapy within 14 days prior to first study treatment with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma. Participants must have recovered (ie, Grade ≤1 or at baseline) from radiation-related toxicities prior to first study treatment. Treatment with complementary medications (e.g., herbal supplements or traditional Chinese medicines) to treat the disease under study within <2 weeks prior to first study treatment. Such medications are permitted if they are used as supportive care. Treatment with any live / attenuated vaccine within 30 days of first study treatment. Co-morbid systemic illnesses or other severe concurrent disease, which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens. Uncontrolled intercurrent illness including, but not limited to: • Ongoing or active infection • Symptomatic CHF (class II and above that are not properly controlled on maintenance therapy or that have been hospitalized in the last 4 weeks for heart failure) • Unstable angina pectoris • Cardiac arrhythmia Or psychiatric illness/social situations that would limit compliance with study requirements. Receiving any other investigational agent, which would be considered as a treatment for the primary neoplasm. Other active malignancy ≤5 years prior to registration. EXCEPTIONS: Squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesions that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years. History of myocardial infarction ≤6 months, or CHF (class II and above that are not properly controlled on maintenance therapy or that have been hospitalized in the last 4 weeks for heart failure) requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias. Patients with known primary CNS malignancy or symptomatic CNS metastases are excluded, with the following exceptions: Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met: o Evaluable or measurable disease outside the CNS o No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm) No history of intracranial hemorrhage or spinal cord hemorrhage No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted. No neurosurgical resection or brain biopsy ≤28 days prior to registration Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following: Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study No stereotactic radiation or whole-brain radiation ≤28 days prior to registration Screening CNS radiographic study ≥4 weeks from completion of radiotherapy and ≥ 2 weeks from discontinuation of corticosteroids a. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or vaccines. 9. b. Patients with a plan to receive yellow fever or other live (attenuated) vaccines during the course of study. 9. c. Patients who have a history or current evidence of bleeding disorder, i.e., any hemorrhage/bleeding event of CTCAE Grade ≥2, ≤28 days prior to registration. 9. d. Patients on supraphysiologic doses of steroids or use of such ≤ 6weeks prior to registration. 9. e. Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease. 9. f. History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. Note: Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible. Patients with controlled Type 1 diabetes mellitus (T1DM) on a stable insulin regimen are eligible. Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: o Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations Rash must cover less than 10% of body surface area (BSA) Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%) No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids). 9. g. History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan. Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted. 9. h. Any infection > Grade 2 ≤4 weeks prior to registration, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. 9. i. History of peripheral neuropathy ≥Grade 2. 10. Subject is Seropositive for HIV. Seropositive for hepatitis B (defined by a positive test for HBsAg). Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for anti-HBc and/or anti-HBs) must be screened using RT-PCR measurement of HBV DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR. Seropositive for hepatitis C (except in the setting of a SVR, defined as aviremia at least 12 weeks after completion of antiviral therapy). 11. COPD with a FEV1 < 50% of predicted normal. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is < 50% of predicted normal. 12. Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification. Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate. 13. Prisoners or subjects who are compulsory detained.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pancreatic Ductal Adenocarcinoma<br> | Drug: Daratumumab<br>* anti-CD38 monoclonal antibody (mAb)<br>* Other names: Darzalex Faspro;Biological: KRAS vaccine<br>* Stimulon QS-21 and Targovax TG01<br>Drug: Nivolumab<br>* anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)<br>* Other names: BMS-936558;|
| Experimental: Refractory Non-Small Cell Lung Cancer<br> | Drug: Daratumumab<br>* anti-CD38 monoclonal antibody (mAb)<br>* Other names: Darzalex Faspro;Biological: KRAS vaccine<br>* Stimulon QS-21 and Targovax TG01<br>Drug: Nivolumab<br>* anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)<br>* Other names: BMS-936558;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Rate (ORR) (Efficacy) | Evaluation of response by ORR by irRECIST criteria. Response classification will follow the irRECIST criteria and will be defined as PR or CR. Patients who are lost to follow-up without a valid response assessment will be classified as NR (non-responder, progression). The ORR will be computed for all patients with at least one cycle of the study drug. | every 8 weeks, approximately 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Incidence rate of Adverse Events | From start of intervention until 30 days following discontinuation of intervention, approximately 2 years | 
| Progression Free Survival (PFS) | PFS will be defined as the time in days from study entry until progression or death. | at 6 months and 9 months | 
| Duration of Response (DOR) | DoR is defined as the length of time tumor continues to respond to the treatment. | approximately 3 years | 
| Clinical Benefit Rate (CBR) | CBR classification will follow the irRECIST criteria and will be defined as the percentage of patients who achieved stable disease (SD) or better response. | approximately 2 years | 
| Overall Survival | OS will be defined as the time in days from study entry until death. All events of death will be included, regardless of whether the event occurred while the subject was still taking study drug, or after the subject discontinued study drug. | approximately 3 years |